Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Mar 05, 2026
|
REGENXBIO Reports Q4 2025 Loss, Misses Revenue and EPS Estimates, Highlights Cash Runway into Early 2027
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is an oncology-focused therapeutic developed by SELLAS, targeting cancer antigens (WT1) and used as an immunotherapy.
|
$526.49M |
$4.09
-18.10%
|
|
RCKT
Rocket Pharmaceuticals, Inc.
Direct gene therapy platform encompassing ex vivo LV and in vivo AAV modalities.
|
$521.63M |
$4.65
-3.53%
|
|
CRMD
CorMedix Inc.
Melinta acquisition adds a diversified antibiotic portfolio expanding revenue mix into infectious disease therapeutics.
|
$515.82M |
$6.92
-4.02%
|
|
ANNX
Annexon, Inc.
Annexon's lead programs are monoclonal antibody therapeutics (ANX005, ANX009) targeting C1q.
|
$515.37M |
$4.67
-6.87%
|
|
TECX
Tectonic Therapeutic, Inc.
TX45 is a recombinant fusion protein (Fc-relaxin) developed using TECX's GEODe platform, fitting the Recombinant Proteins & Enzymes category.
|
$513.01M |
$27.86
+1.64%
|
|
ENGN
enGene Holdings Inc.
engGene's core platform is non-viral gene therapy delivery (DDX platform) and its lead asset is a gene therapy product, placing it squarely in Gene Therapy.
|
$498.61M |
$8.73
-10.32%
|
|
ANRO
Alto Neuroscience, Inc.
Company focuses on Neuropsychiatric drug development across MDD, bipolar depression, TRD, and schizophrenia using precision psychiatry.
|
$495.50M |
$19.34
+5.71%
|
|
NMRA
Neumora Therapeutics, Inc. Common Stock
Company focuses on neuropsychiatric drug development, including navacaprant for major depressive disorder, aligning with Neuropsychiatric Drug Development.
|
$493.93M |
$3.00
-1.64%
|
|
MYGN
Myriad Genetics, Inc.
Companion diagnostics—biomarker-based tests that stratify patients for targeted therapies; aligns with Myriad's genetic tests.
|
$492.17M |
$5.13
-2.84%
|
|
ASPI
ASP Isotopes Inc. Common Stock
ASPI’s PET Labs Radiopharmaceuticals production and enriched isotopes are delivered as a core product line.
|
$488.06M |
$5.12
-3.67%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Fanapt and other marketed/potential small-molecule therapies (e.g., Tradipitant) are oral small molecule therapeutics.
|
$484.59M |
$7.92
-3.41%
|
|
SLDB
Solid Biosciences Inc.
Solid Biosciences is developing viral-vector gene therapies (SGT-3.00, SGT-212, SGT-501) and related products, fitting squarely under Biotech - Gene Therapy.
|
$478.12M |
$5.61
-8.71%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$477.74M |
$11.66
-6.72%
|
|
ADCT
ADC Therapeutics S.A.
ADCT's lead product ZYNLONTA is an antibody-drug conjugate (ADC), directly aligning with the Antibody-Drug Conjugates category.
|
$477.00M |
$4.18
-1.42%
|
|
ETON
Eton Pharmaceuticals, Inc.
ETON's strategic focus on ultra-rare diseases and a portfolio of therapies for rare conditions aligns with the Biotech - Rare Diseases investable theme.
|
$470.11M |
$17.24
-1.65%
|
|
ZVRA
Zevra Therapeutics, Inc.
Zevra focuses on rare-disease therapeutics (NPC, UCD, VEDS) and related pipeline assets, core to rare disease biotech.
|
$466.48M |
$8.48
+2.05%
|
|
LRMR
Larimar Therapeutics, Inc.
Nomlabofusp is a recombinant fusion protein, i.e., a recombinant protein/enzyme therapeutic.
|
$466.47M |
$5.23
-4.04%
|
|
RGNX
REGENXBIO Inc.
Core product category: gene therapy using NAV AAV platform.
|
$461.70M |
$8.72
-4.54%
|
|
EBS
Emergent BioSolutions Inc.
EBS directly develops and manufactures vaccines and vaccine-derived MCMs (BioThrax, ACAM2000, TEMBEXA) for government/public health programs.
|
$460.60M |
$8.43
-3.88%
|
|
LYEL
Lyell Immunopharma, Inc.
Lyell’s lead program LYL314 is a CAR-T cell therapy product targeting cancer (CD19/CD20 dual-target), the core business.
|
$457.23M |
$22.09
-7.18%
|
|
SIGA
SIGA Technologies, Inc.
SIGA's core product is TPOXX, a small-molecule antiviral for orthopoxviruses, directly produced and marketed by the company.
|
$456.13M |
$6.25
-1.96%
|
|
FULC
Fulcrum Therapeutics, Inc.
Fulcrum's lead asset pociredir is an oral small molecule therapeutic intended to induce HbF in SCD.
|
$451.89M |
$8.15
-2.40%
|
|
AVXL
Anavex Life Sciences Corp.
Company's lead product and pipeline consist of oral small-molecule therapeutics (ANAVEX 2-73 and ANAVEX 3-71).
|
$446.74M |
$4.78
-4.40%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics' core business is developing allogeneic cell therapy platforms and products (OpRegen, OPC1, ReSonance ANP1).
|
$445.29M |
$1.84
-5.64%
|
|
ENTA
Enanta Pharmaceuticals, Inc.
Enanta is actively developing antiviral small-molecule therapeutics targeting RSV, fitting the Antiviral Small-Molecule Therapeutics theme.
|
$444.77M |
$13.73
-10.87%
|
|
AQST
Aquestive Therapeutics, Inc.
Aquestive's PharmFilm drug-delivery platform enables non-invasive, thin-film administration of complex molecules; Anaphylm and Libervant employ this platform.
|
$435.79M |
$4.26
-2.52%
|
|
AUTL
Autolus Therapeutics plc
Core product: obe-cel CAR-T cell therapy (cell therapy) for rr B-ALL.
|
$433.81M |
$1.49
-8.90%
|
|
FLGT
Fulgent Genetics, Inc.
Contract Research Organization services for bioPharma.
|
$432.46M |
$14.25
+1.86%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$420.49M |
$7.67
-1.60%
|
|
FDMT
4D Molecular Therapeutics, Inc.
Inhibitory miRNA and oligonucleotide components described in 4D-150 suggest an oligonucleotide therapeutics approach.
|
$417.05M |
$8.62
-3.47%
|
Showing page 11 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
